|
Name |
3-Hydroxy-4-deoxypaxilline
|
Molecular Formula | C27H35NO3 | |
IUPAC Name* |
(1S,2S,5S,7S,8R,14S)-7-(2-hydroxypropan-2-yl)-1,2-dimethyl-6-oxa-23-azahexacyclo[12.10.0.02,11.05,10.016,24.017,22]tetracosa-9,16(24),17,19,21-pentaen-8-ol
|
|
SMILES |
C[C@]12CC[C@H]3C(=C[C@H]([C@H](O3)C(C)(C)O)O)C1CC[C@@H]4[C@@]2(C5=C(C4)C6=CC=CC=C6N5)C
|
|
InChI |
InChI=1S/C27H35NO3/c1-25(2,30)24-21(29)14-18-19-10-9-15-13-17-16-7-5-6-8-20(16)28-23(17)27(15,4)26(19,3)12-11-22(18)31-24/h5-8,14-15,19,21-22,24,28-30H,9-13H2,1-4H3/t15-,19?,21+,22-,24-,26-,27+/m0/s1
|
|
InChIKey |
FROHWGGMFSFTTA-QBCJVXSESA-N
|
|
Synonyms |
PC-M6; 3-Hydroxy-4-deoxypaxilline; 10-Hydroxy-13-deoxypaxilline; PC-M-6; CHEBI:192187; (1S,2S,5S,7S,8R,14S)-7-(2-hydroxypropan-2-yl)-1,2-dimethyl-6-oxa-23-azahexacyclo[12.10.0.02,11.05,10.016,24.017,22]tetracosa-9,16(24),17,19,21-pentaen-8-ol
|
|
CAS | 133613-76-0 | |
PubChem CID | 101590875 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 421.6 | ALogp: | 4.6 |
HBD: | 3 | HBA: | 3 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 65.5 | Aromatic Rings: | 6 |
Heavy Atoms: | 31 | QED Weighted: | 0.562 |
Caco-2 Permeability: | -4.745 | MDCK Permeability: | 0.00001600 |
Pgp-inhibitor: | 0.995 | Pgp-substrate: | 0.684 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.01 |
30% Bioavailability (F30%): | 0.017 |
Blood-Brain-Barrier Penetration (BBB): | 0.525 | Plasma Protein Binding (PPB): | 91.48% |
Volume Distribution (VD): | 1.455 | Fu: | 4.16% |
CYP1A2-inhibitor: | 0.183 | CYP1A2-substrate: | 0.775 |
CYP2C19-inhibitor: | 0.12 | CYP2C19-substrate: | 0.744 |
CYP2C9-inhibitor: | 0.35 | CYP2C9-substrate: | 0.097 |
CYP2D6-inhibitor: | 0.278 | CYP2D6-substrate: | 0.237 |
CYP3A4-inhibitor: | 0.901 | CYP3A4-substrate: | 0.631 |
Clearance (CL): | 7.103 | Half-life (T1/2): | 0.024 |
hERG Blockers: | 0.069 | Human Hepatotoxicity (H-HT): | 0.125 |
Drug-inuced Liver Injury (DILI): | 0.042 | AMES Toxicity: | 0.015 |
Rat Oral Acute Toxicity: | 0.96 | Maximum Recommended Daily Dose: | 0.907 |
Skin Sensitization: | 0.11 | Carcinogencity: | 0.826 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.015 |
Respiratory Toxicity: | 0.985 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005989 | 1.000 | D0H4JM | 0.306 | ||||
ENC005406 | 0.776 | D01JGV | 0.286 | ||||
ENC002951 | 0.773 | D0U7GP | 0.286 | ||||
ENC002279 | 0.758 | D0K0KH | 0.244 | ||||
ENC005990 | 0.615 | D08QKJ | 0.240 | ||||
ENC003933 | 0.602 | D05MQK | 0.239 | ||||
ENC000857 | 0.596 | D02STN | 0.237 | ||||
ENC005988 | 0.584 | D04RLY | 0.236 | ||||
ENC005405 | 0.583 | D0Q6NZ | 0.234 | ||||
ENC002707 | 0.573 | D09HDR | 0.234 |